The debate about whether IL-6 targeted agents improve clinical outcomes for severe COVID-19 patients will continue, but it also prompts us to think more deeply about the application of cytokine antagonists in COVID-19, such as identifying those who are most likely to benefit from cytokine therapy and the optimal timing for the administration of drugs during the disease course. The gene discussed is IL6; the disease is COVID-19.